Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Phosphatidylinositol 3-kinase-delta (PI3Kδ) signaling is critical for proliferation, survival, homing, and tissue retention of malignant B cells. Idelalisib, a selective oral inhibitor of PI3Kδ, has shown considerable single-agent activity in patients with heavily pretreated chronic lymphocytic leuk...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Hemasphere
Huvudupphovsmän: Coutre, Steven E., Flinn, Ian W., de Vos, Sven, Barrientos, Jacqueline C., Schreeder, Marshall T., Wagner-Johnson, Nina D., Sharman, Jeff P., Boyd, Thomas E., Fowler, Nathan, Dreiling, Lyndah, Kim, Yeonhee, Mitra, Siddhartha, Rai, Kanti, Leonard, John P., Furman, Richard R.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Wolters Kluwer Health 2018
Ämnen:
Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6745995/
https://ncbi.nlm.nih.gov/pubmed/31723767
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HS9.0000000000000039
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk